International Journal of Molecular Sciences, 23 November 2019
Endocannabinoid system consists of cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands, and the enzymes responsible for their synthesis and degradation. CB2, to a great extent, and CB1, to a lesser extent, are involved in regulating the im…
Archive for month: November, 2019
Kevin M. Takakuwa, MD and Dr. Dustin Sulak evaluate how US medical professionals received their cannabis medicine training in Mary Ann Liebert, Inc.
European Journal of Obstetrics & Gynecology and Reproductive Biology, 15 November 2019
Endometriosis affects a large proportion of women during their reproductive years and is associated with pain and infertility, also affecting psychological wellbeing and quality of life. The pathogenesis of the disease remains unclear, although it is believed to be multifactor…
Genester Wilson-King, MD and Dr. Michael Eisenberg are conducting research on cannabis and sexual health at Stanford University. The survey will provide an opportunity for the general public to participate in cannabis research.
The Journal of Pain, 9 November 2019
Use of cannabis to alleviate headache and migraine is relatively common, yet research on its effectiveness remains sparse. We sought to determine whether inhalation of cannabis decreases headache and migraine ratings as well as whether gender, type of cannabis (concentrate vs…
European Journal of Pharmacology, 5 November 2019
The biological effects of endocannabinoid system are mediated by two types of receptors, cannabinoid 1 (CB1) and cannabinoid 2 receptor (CB2). They play a pivotal role in the management of pain, inflammation, cancer, obesity and diabetes mellitus. CB2 receptor activity downreg…